CME Group Inc (CME) concluded trading on Wednesday at a closing price of $256.72, with 4.09 million shares of worth about $1.05 billion changed hands on the day. Half year performance of the stock remained positive as price took a surge of 20.39% during that period and on March 12, 2025 the price saw a loss of about -1.42%. Currently the company’s common shares owned by public are about 359.60M shares, out of which, 359.21M shares are available for trading.
Stock saw a price change of 0.88% in past 5 days and over the past one month there was a price change of 6.17%. Year-to-date (YTD), CME shares are showing a performance of 10.55% which increased to 23.53% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $186.08 but also hit the highest price of $263.65 during that period. The average intraday trading volume for CME Group Inc shares is 1.94 million. The stock is currently trading 1.83% above its 20-day simple moving average (SMA20), while that difference is up 6.29% for SMA50 and it goes to 17.86% higher than SMA200.
CME Group Inc (NASDAQ: CME) currently have 359.60M outstanding shares and institutions hold larger chunk of about 89.41% of that.
The stock has a current market capitalization of $92.51B and its 3Y-monthly beta is at 0.44. PE ratio of stock for trailing 12 months is 26.54, while it has posted earnings per share of $9.67 in the same period. Its PEG reads 4.87 while making debt-to-equity ratio of 0.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CME, volatility over the week remained 2.60% while standing at 1.95% over the month.
Stock’s fiscal year EPS is expected to rise by 3.15% while it is estimated to increase by 5.57% in next year. EPS is likely to shrink at an annualized rate of 5.45% for next 5-years, compared to annual growth of 10.36% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on March 10, 2025 offering an Outperform rating for the stock and assigned a target price of $287 to it. Coverage by Citigroup stated CME Group Inc (CME) stock as a Neutral in their note to investors on January 06, 2025, suggesting a price target of $250 for the stock. On October 08, 2024, Redburn Atlantic Downgrade their recommendations, while on September 27, 2024, RBC Capital Mkts Initiated their ratings for the stock with a price target of $235. Stock get a Hold rating from TD Cowen on September 26, 2024.
